The double-blind, placebo-controlled phase 3 THRIVE-AA1 (NCT04518995) and THRIVE-AA2 (NCT04797650) trials in patients with severe alopecia areata (AA) evaluated the efficacy of deuruxolitinib in patients with ≥50% scalp hair loss (as measured by the Severity of Alopecia Tool, SALT). The trials’ primary endpoint, a SALT score ≤20 at week 24, was achieved by 31% of participants in the deuruxolitinib 8 mg twice-daily group, compared with 0.8% in the placebo group. The objective of the current post-hoc analysis was to examine the change in patient-reported hair satisfaction over 24 weeks in adult patients with AA who responded to deuruxolitinib 8 mg twice daily in a pooled analysis of the THRIVE-AA1 and THRIVE-AA2 trial1.
Most participants had very significant hair loss. In both studies, 31.0% of participants randomised to deuruxolitinib achieved a SALT score ≤20 at week 24 and were included in the current analysis. The shift in hair satisfaction among responders to deuruxolitinib was assessed in the 5-point Hair Satisfaction Patient Reported Outcome (SPRO) scale.
By week 24, 95.7% of participants treated with deuruxolitinib who were initially dissatisfied with their hair reported satisfaction (P<0.0001). This shift occurred progressively. “As early as week 12, we saw impressive results: 79% of participants flipped from very dissatisfied to satisfied or very satisfied,” said Dr Paradi Mirmirani (Kaiser Permanente Vallejo Medical Center, CA, USA). No participants in the placebo group achieved similar outcomes.
These findings underscore the efficacy of deuruxolitinib in not only promoting hair regrowth but also improving patients’ overall satisfaction with their appearance.
Medical writing support was provided by Dr Susanne Kammerer